EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Lignocaine or hyaluronidase – Which causes more adverse drug reaction in regional ophthalmic anesthesia? A retrospective study

Jaichandran V Venkatakrishnan

Indian Journal of Ophthalmology · 2024

DOI: 10.4103/ijo.ijo_879_23 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Indian Journal of Ophthalmology, 2024. Verfasst von Jaichandran V Venkatakrishnan. Beteiligte Einrichtung: Department of Anesthesiology, Sankara Nethralaya, Chennai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Hyaluronoglucosaminidase, Anesthetics, Local, Lidocaine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allergic reaction to a local anesthetic solution is rare.[1] On literature review of cases, a total of four cases have been reported to have an allergic reaction to lignocaine, whereas around 40 cases have been reported to have an allergic reaction to hyaluronidase.[2-5] Routine preoperative skin test with lignocaine has been performed earlier.[6] But none of the authors have performed routine preoperative skin test with hyaluronidase. For the past 1½ years, at our institution, we have been following a new preoperative allergic skin test policy. Patients scheduled for eye surgery under regional anesthesia and those with a history of bronchial asthma, allergic rhinitis, food allergy, insect bite allergy, allergy to pollens, allergy to any medicine, and presence of any allergic skin conditions undergo an intradermal skin test with both lignocaine and hyaluronidase mixed together. In case the above set of patients posted either for other eye surgeries or subsequent eye surgeries, the same allergic skin test was repeated, even if the result was negative earlier. On the day of surgery, the nurse establishes an intravenous (IV) line, connects monitors (electrocardiogram, noninvasive blood pressure, and pulse oximeter), and measures vitals (blood pressure, heart rate, and arterial oxygen saturation). Over the patient’s forearm, about four fingers below the antecubital fossa, the skin is cleaned with an alcohol swipe and left to dry. Using 1 ml tuberculin syringe attached to 26-gauge needle, with the bevel facing upward, around 0.1–0.2 ml of 2% lignocaine HCl with preservative (Lox 2% Neon) + hyaluronidase 15 IU/ml (Hynidase) solution is injected intradermally. The intradermal site of injection is marked around with a pen. For every 5 min, vitals are noted for a total of 15 min. Also, patients are monitored for the presence of erythema, induration, wheal, itching around the injection site/any parts of the body, or presence of hypotension. If any of the above-mentioned reaction occurs, then test result is considered as positive. In such patients, intradermal test is performed in the opposite forearm, separately for 2% lignocaine HCl without preservative (Loxicard, Neon), hyaluronidase, and 0.75% ropivacaine without preservative (Ropizuva, Abbott). If reaction occurs for Loxicard, then the test is considered positive for lignocaine per se. Regional anesthesia is then administered with ropivacaine mixed with hyaluronidase. For hyaluronidase intradermal test, 1 ml of normal saline is added to the powdered form of hyaluronidase. It is diluted with 9 ml of normal saline; 1 ml of the solution is withdrawn and again diluted with 9 ml of normal saline. From the above solution, around 0.1–0.2 ml is used to perform the intradermal test with the help of 1 ml tuberculin syringe. For all patients, hyaluronidase is freshly reconstituted, just before injection. It is stored inside the operation theater at a temperature of less than 25°C. Patients in whom skin test had been performed are informed to look for any hardness and redness at the skin test area, even after surgery. If there is any, we encourage them to take photographs and share with the consultant on the first postoperative day. To identify which among lignocaine and hyaluronidase caused more adverse drug reaction, preoperative allergic skin test results from 2021 September to 2022 September were analyzed retrospectively. Institutional ethics committee review board approval was obtained. Incidence rate for positive test reaction was calculated by the number of incidence and percentage. A total of 1628 allergic skin test results were analyzed. Out of these, six test results were found to be positive for hyaluronidase. The demographic details of those six patients, their allergy history, details and management of adverse drug reaction, and surgery details are shown in Table 1. The incidence rate for positive test result to hyaluronidase was found to be 0.37%, while there was no positive test result to lignocaine (P < 0.001). Five patients required pre-sensitization with hyaluronidase. All of them were treated with Inj. hydrocortisone and chlorpheniramine.Table 1: Details of demography and adverse drug reactions that occurred in the six patientsLiterature review showed that the incidence of local allergic reaction to hyaluronidase ranges from 0.05% to 0.69%.[5,7-9] The incidence of mild allergic reactions could be higher because they may have been unrecognized.[5] In our study, we found a similar incidence rate of 0.37%. The higher incidence rate of allergic reaction to hyaluronidase following ocular administration is due to longer residence time compared to that in other tissues that have a dense vascular network.[10] Greater exposure to the drug might allow for a greater degree of primary sensitization leading to hypersensitivity type of reaction following subsequent exposure.[10] Out of the six patients, two patients were known to be bronchial asthmatic and two patients were known to have allergic rhinitis. The remaining two patients did not have any history of allergy and they were administered peribulbar anesthesia with lignocaine and bupivacaine along with hyaluronidase. But they developed periorbital swelling in the immediate postoperative period. On probing history, both these patients admitted that they had slight swelling over the operated eye following injection with local anesthetics administered elsewhere earlier for the other (first) eye. They were then subjected to intradermal skin test for lignocaine and hyaluronidase. They were found to be positive for hyaluronidase and treated conservatively with IV steroids and chlorpheniramine. Following this incident, we began to strictly implement the step that during preoperative evaluation, a leading question should be asked to probe for any periorbital swelling if the patient had undergone an eye surgery under local anesthesia earlier. Hyaluronidase is a protein derived from bovine or ovine testes, and it is generally purified through a series of multiple precipitation, fractionation, and filtration steps.[5] The enzyme obtained with this procedure is impure, immunogenic, and has contaminating substances such as proteases, immunoglobulin, and vasoactive factors.[5] They might potentially cause immediate Type I (mediated by IgE) and delayed Type IV (mediated by T cells) hypersensitivity reactions. Concerning the reactions mediated by IgE, a study in pediatric oncological populations sensitized by IV hyaluronidase treatment or by cross-reactivity with other IgE antibodies showed that anaphylactic reactions were the most severe, and immediate allergic reactions were observed after IV administrations of chemotherapeutics.[11] Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of hyaluronidase preparation Neopermease revealed two major bands at 73 and 41–43 kDa, respectively.[11] A specific inhibition of IgE binding to both bands was achieved after preincubation of the sera with partially purified bovine hyaluronidase. In our study, out of those six patients, two patients were known to be asthmatic and two patients were known to have allergic rhinitis. In bronchial asthmatic and allergic rhinitis patients, Whether any preformed specific IgE antibodies found in bronchial asthmatic and allergic rhinitis patients has any cross-reaction with the IgE antibodies specific to hyaluronidase remains to be elucidated. Unlike the ester type, allergy to an amide type of local anesthetic agent does not contraindicate the use of another amide type of local anesthetic agent. Still there are reported cases where lignocaine has shown cross sensitivity with mepivacaine (amide).[12,13] It would be unwise to use another amide local anesthetic without hypersensitivity tests. Thus, in our skin test policy too, if there is any positive reaction to combined lignocaine and hyaluronidase, we have included ropivacaine, which is preservative free, to be given in the opposite forearm. In an ophthalmic setup, turnover of cases is higher. The total number of cataract surgeries performed in a single day may vary from 100 to 200. It is a difficult task to administer test dose for all cases and observe them for vitals every 5 min before shifting them to the operation theater. Hence, considering the logistical issues involved, it was decided that we would administer preoperative test dose for a selected group of allergy-defined patients. From this study, it can be concluded that hyaluronidase caused more adverse reaction than the local anesthetic agent itself. Hence, both ophthalmologists and anesthesiologists involved should consider performing preoperative allergic skin test for hyaluronidase, especially in patients with history of any allergies. In nonallergic patients, if the patient gives history of eye swelling or itching during the previous eye surgery, skin test has to be done. Allergic skin test for hyaluronidase is not only a good clinical practice, but also justified from medicolegal point of view.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyaluronoglucosaminidaseAnesthetics, LocalLidocaineHumansRetrospective StudiesOphthalmologic Surgical ProceduresMaleFemaleAnesthesia, ConductionAnesthesia, LocalMiddle Aged

Substanzen

HyaluronoglucosaminidaseAnesthetics, LocalLidocaine

Autor:innen und Institutionen

  • Department of Anesthesiology, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Zitieren

APA

Venkatakrishnan, J. V. (2024). Lignocaine or hyaluronidase – Which causes more adverse drug reaction in regional ophthalmic anesthesia? A retrospective study. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_879_23

Vancouver

Venkatakrishnan JV. Lignocaine or hyaluronidase – Which causes more adverse drug reaction in regional ophthalmic anesthesia? A retrospective study. Indian Journal of Ophthalmology. 2024. doi:10.4103/ijo.ijo_879_23

BibTeX
@article{Venkatakrishnan2024,
  author = {Venkatakrishnan, Jaichandran V},
  title = {Lignocaine or hyaluronidase – Which causes more adverse drug reaction in regional ophthalmic anesthesia? A retrospective study},
  journal = {Indian Journal of Ophthalmology},
  year = {2024},
  doi = {10.4103/ijo.ijo_879_23}
}
Kostenlos starten →